Pulmatrix, Inc. Common Stock (PULM) Stock Price

PULMStock

$1.49−68.93%52W

Market Cap$5.42M

P/E—

PEG Ratio—

Div yield—

Beta2.00

PULM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-63.53%

Price vs S&P 500 (4W)-14.76%

VGM Score45.43

Book Value / Share (Quarterly)$0.98

P/TBV (Annual)1.01x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.72%

Cash Flow / Share (Quarterly)$-1.28

Price vs S&P 500 (YTD)-44.90%

Net Profit Margin (TTM)-122.46%

EPS (TTM)$-1.41

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-1.41

Revenue Growth (5Y)-0.26%

EPS (Annual)$-1.41

ROI (Annual)-135.49%

Net Profit Margin (5Y Avg)-233.87%

Cash / Share (Quarterly)$0.91

ROA (Last FY)-124.72%

Revenue Growth TTM (YoY)-99.97%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-84.77%

Operating Margin (TTM)-125.07%

Cash Flow / Share (Annual)$-1.49

P/B Ratio1.54x

P/B Ratio (Quarterly)1.31x

Net Income / Employee (Annual)$-2,581,000

EV / Revenue (TTM)0.28x

Net Interest Coverage (TTM)-127.50x

ROA (TTM)-88.53%

EPS Incl Extra (Annual)$-1.41

Current Ratio (Annual)12.55x

Quick Ratio (Quarterly)4.58x

3-Month Avg Trading Volume0.04M

52-Week Price Return-68.93%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$125.14

P/S Ratio (Annual)0.71x

Asset Turnover (Annual)0.79x

52-Week High$5.50

Operating Margin (5Y Avg)-221.49%

EPS Excl Extra (Annual)$-1.41

CapEx CAGR (5Y)46.00%

26-Week Price Return-51.60%

Quick Ratio (Annual)12.53x

13-Week Price Return11.03%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.96x

Enterprise Value$2.20M

Revenue / Share Growth (5Y)-25.66%

Asset Turnover (TTM)0.46x

Book Value / Share Growth (5Y)-39.42%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-122.46%

Cash / Share (Annual)$1.12

3-Month Return Std Dev53.09%

Net Income / Employee (TTM)$-2,581,000

ROE (Last FY)-135.49%

Net Interest Coverage (Annual)-45.32x

EPS Basic Excl Extra (Annual)$-1.41

Receivables Turnover (TTM)6.56x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.41

Receivables Turnover (Annual)16.82x

ROI (TTM)-96.97%

P/S Ratio (TTM)0.71x

Pretax Margin (5Y Avg)-233.87%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$125.14

Price vs S&P 500 (52W)-87.49%

Year-to-Date Return-32.29%

5-Day Price Return-2.58%

EPS Normalized (Annual)$-1.41

ROA (5Y Avg)-68.55%

Net Profit Margin (Annual)-122.46%

Month-to-Date Return-13.22%

Cash Flow / Share (TTM)$-4.42

EBITD / Share (Annual)$-1.42

Operating Margin (Annual)-125.07%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-84.77%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.41

P/TBV (Quarterly)1.01x

P/B Ratio (Annual)2.14x

Pretax Margin (TTM)-122.46%

Book Value / Share (Annual)$1.04

Price vs S&P 500 (13W)9.07%

Beta2.00x

P/FCF (Annual)1.74x

Revenue / Share (TTM)$0.00

ROE (TTM)-96.97%

52-Week Low$1.16

vGradeA

gGradeF

mGradeD

vgmGradeC

PULM Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2023	Nov 9, 2023	-$1.05	-$1.03	+1.90%(+$0.02)
Q2 2023	Aug 10, 2023	-$1.23	-$1.04	+15.45%(+$0.19)
Q4 2022	Mar 30, 2023	-$1.44	-$1.14	+20.83%(+$0.30)

PULM Analyst Recommendations

Dec 2024

Jan 2025

Feb 2025

Mar 2025

4.14

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
PULMPulmatrix, Inc. Common Stock	A	F	D	$1.49
LLYEli Lilly & Co.	D	B	C	$1153.58
JNJJohnson & Johnson	D	C	B	$266.27
ABBVABBVIE INC.	D	C	B	$255.65
MRKMerck & Co., Inc.	D	C	B	$147.59
NVSNovartis AG	C	C	C	$152.33
AZNAstraZeneca PLC	C	B	C	$162.75
NVONovo-Nordisk A/S	B	C	C	$45.38
ABTAbbott Laboratories	C	C	C	$110.32
PFEPfizer Inc.	C	D	B	$28.21
VRTXVertex Pharmaceuticals Inc	D	C	B	$537.93
BMYBristol-Myers Squibb Co.	B	B	B	$66.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.49
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.34
REGNRegeneron Pharmaceuticals Inc	C	C	B	$792.83
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.00
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$35.86
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$355.93
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$61.15
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$241.11
ZTSZOETIS INC.	C	C	D	$76.84
INSMInsmed, Inc.	F	A	C	$120.53
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.81
UTHRUnited Therapeutics Corp	C	C	B	$509.27
GMABGenmab A/S ADS	C	C	B	$33.05
VTRSViatris Inc. Common Stock	B	C	B	$16.32
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$262.64
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$249.91
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$75.62
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$65.31
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$526.32
CORTCorcept Therapeutics Inc.	F	C	B	$112.35
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$23.88
ARWRArrowhead Research Corporation	D	A	B	$81.65
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.57
AXSMAxsome Therapeutics, Inc	D	B	C	$198.58
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.16
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$59.85
ABVXAbivax SA American Depositary Shares	—	—	C	$113.22
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
CYTKCytokinetics Inc.	F	D	C	$70.53
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$338.00
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.19
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.98
TGTXTG Therapeutics, Inc.	D	B	B	$53.31
ALKSAlkermes Inc. plc	D	C	B	$46.87
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$88.80
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$105.52
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.28
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$152.21
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$17.43

About Pulmatrix, Inc. Common Stock

Pulmatrix is a biopharmaceutical company developing inhaled therapies for migraine and respiratory diseases using its proprietary iSPERSE dry powder delivery platform. Its clinical pipeline includes PUR3100 for acute migraine, PUR1800 for COPD exacerbations, and PUR1900 for aspergillosis in asthma and cystic fibrosis patients, targeting significant unmet medical needs.